Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Erik Eik Anda*,1,&,
- Tonje Braaten*,1,
- Kristin B. Borch*,1,
- Therese H. Nøst*,1,
- Sairah L. F. Chen1,
- Marko Lukic1,
- Eiliv Lund1,
- Frode Forland2,
- David Leon1,3,
- Brita Askeland Winje2,
- Anne-Marte Bakken Kran2,
- Mette Kalager4,
- Fridtjof Lund Johansen5 and
- Torkjel M. Sandanger#,1
- 1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
- 2Norwegian Institute of Public Health, Oslo, Norway
- 3Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
- 4Clinical Effectiveness Research Group, University of Oslo and Oslo University Hospital, Oslo, Norway
- 5Department of Immunology, Oslo University Hospital, Rikshospitalet, Norway
- ↵&Corresponding author
: Erik Eik Anda, Department of Community Medicine, UiT The Arctic University of Norway, email: erik.anda{at}uit.no
Posted March 26, 2021.
Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period
